Lineage Cell Therapeutics Q2 EPS Reduced by HC Wainwright

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Investment analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.02) for the quarter, down from their prior estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q4 2026 earnings at $0.00 EPS and FY2027 earnings at ($0.07) EPS.

Other equities analysts also recently issued reports about the company. B. Riley Financial lifted their target price on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Canaccord Genuity Group assumed coverage on Lineage Cell Therapeutics in a research report on Tuesday, April 28th. They issued a “buy” rating and a $9.00 target price for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, May 4th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $6.25.

Lineage Cell Therapeutics Price Performance

NYSEAMERICAN LCTX opened at $1.31 on Friday. The company has a market cap of $326.58 million, a P/E ratio of -4.52 and a beta of 1.60. The stock has a 50-day moving average of $1.55 and a two-hundred day moving average of $1.67. Lineage Cell Therapeutics has a 1-year low of $0.45 and a 1-year high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The business had revenue of $1.73 million for the quarter, compared to analyst estimates of $3.60 million. Lineage Cell Therapeutics had a negative return on equity of 89.36% and a negative net margin of 434.44%.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Defender Capital LLC. acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth about $11,405,000. Define Financial LLC acquired a new position in shares of Lineage Cell Therapeutics during the fourth quarter worth about $33,000. Nwam LLC grew its position in shares of Lineage Cell Therapeutics by 133.3% during the third quarter. Nwam LLC now owns 35,000 shares of the company’s stock worth $56,000 after buying an additional 20,000 shares in the last quarter. Red Crane Wealth Management LLC grew its position in shares of Lineage Cell Therapeutics by 3.1% during the third quarter. Red Crane Wealth Management LLC now owns 511,363 shares of the company’s stock worth $864,000 after buying an additional 15,365 shares in the last quarter. Finally, Citizens Financial Group Inc. RI acquired a new position in shares of Lineage Cell Therapeutics during the third quarter worth about $25,000. 62.47% of the stock is owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.